Immunocore Holdings (6YG) Financial Statements
Immunocore Holdings Financial Overview
Immunocore Holdings's market cap is currently $1.41B. The company's EPS TTM is $-0.18; its P/E ratio is -169.11; Immunocore Holdings is estimated to report earnings on November 11, 2026, and the estimated EPS forecast is $-0.12. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 297.57M | $ 247.98M | $ 197.39M | $ 144.23M | $ 27.04M |
| Gross Profit | $ 291.36M | $ 242.44M | $ 196.57M | $ 138.94M | $ 27.04M |
| Operating Income | $ -33.74M | $ -56.28M | $ -47.20M | $ -42.77M | $ -129.42M |
| EBITDA | $ 387.18K | $ -37.66M | $ -40.87M | ― | ― |
| Net Income | $ -26.42M | $ -40.81M | $ -43.75M | $ -43.46M | $ -133.45M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 864.15M | $ 820.38M | $ 350.27M | $ 402.47M | $ 321.06M |
| Total Assets | $ 1.07B | $ 1.01B | $ 472.44M | $ 526.76M | $ 407.28M |
| Total Debt | $ 436.69M | $ 432.72M | $ 66.50M | $ 81.45M | $ 86.16M |
| Net Debt | $ -31.02M | $ -23.01M | $ -283.77M | $ -321.02M | $ -234.90M |
| Total Liabilities | $ 686.24M | $ 648.79M | $ 180.55M | $ 187.86M | $ 175.76M |
| Stockholders' Equity | $ 381.03M | $ 360.72M | $ 291.89M | $ 338.90M | $ 231.53M |
| Cash Flow | |||||
| Free Cash Flow | $ -11.20M | $ 20.89M | $ -1.97M | $ -51.41M | $ -144.49M |
| Operating Cash Flow | $ -7.97M | $ 26.06M | $ 2.33M | $ -49.21M | $ -143.11M |
| Investing Cash Flow | $ -12.16M | $ -355.13M | $ -4.29M | $ -2.20M | $ -1.28M |
| Financing Cash Flow | $ 9.20M | $ 343.88M | $ 27.18M | $ 145.44M | $ 288.19M |
Currency in GBP
